Allergan plc (AGN) Reaches $145.50 52-Week Low; Mid Penn Bancorp Has 0.75 Sentiment

March 2, 2018 - By Adrian Mccoy

The stock of Allergan plc (NYSE:AGN) hit a new 52-week low and has $139.68 target or 4.00% below today’s $145.50 share price. The 8 months bearish chart indicates high risk for the $48.06 billion company. The 1-year low was reported on Mar, 2 by If the $139.68 price target is reached, the company will be worth $1.92B less. The stock decreased 1.82% or $2.69 during the last trading session, reaching $145.5. About 2.11 million shares traded. Allergan plc (NYSE:AGN) has declined 3.42% since March 2, 2017 and is downtrending. It has underperformed by 20.12% the S&P500.

Mid Penn Bancorp, Inc. operates as the holding firm for Mid Penn Bank that provides commercial banking and trust business services to individuals, partnerships, non-profit organizations, and firms in Pennsylvania. The company has market cap of $194.34 million. It offers various time and demand deposit products, including checking accounts, savings accounts, clubs, money market deposit accounts, certificates of deposit, and individual retirement accounts. It has a 18.98 P/E ratio. The firm also provides a range of loan products comprising installment loans, mortgage and home equity loans, secured and unsecured commercial and consumer loans, lines of credit, construction financing, farm loans, community development loans, loans to non-profit entities, and local government loans.

It closed at $31.75 lastly. It is down 80.96% since March 2, 2017 and is uptrending. It has outperformed by 64.26% the S&P500.

Since January 1, 0001, it had 3 buys, and 0 selling transactions for $74,440 activity.

Zpr Investment Management holds 0.66% of its portfolio in Mid Penn Bancorp, Inc. for 14,710 shares. Wharton Business Group Llc owns 25,737 shares or 0.08% of their US portfolio. Moreover, Bryn Mawr Trust Co has 0.04% invested in the company for 22,452 shares. The Pennsylvania-based Emerald Advisers Inc Pa has invested 0.04% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 37,848 shares.

Among 28 analysts covering Allergan Inc. (NYSE:AGN), 20 have Buy rating, 0 Sell and 8 Hold. Therefore 71% are positive. Allergan Inc. has $400 highest and $171.0 lowest target. $256.83’s average target is 76.52% above currents $145.5 stock price. Allergan Inc. had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Deutsche Bank on Friday, August 7. The rating was maintained by Mizuho with “Buy” on Friday, November 13. The firm has “Buy” rating by Vetr given on Monday, August 24. The stock of Allergan plc (NYSE:AGN) has “Hold” rating given on Tuesday, August 29 by Cantor Fitzgerald. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, January 4 report. Goldman Sachs downgraded the stock to “Neutral” rating in Wednesday, May 10 report. Susquehanna maintained Allergan plc (NYSE:AGN) on Wednesday, January 17 with “Hold” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, September 20. The firm earned “Buy” rating on Thursday, October 19 by Citigroup. On Thursday, March 1 the stock rating was maintained by Credit Suisse with “Buy”.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $48.06 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

Analysts await Allergan plc (NYSE:AGN) to report earnings on May, 8. They expect $3.35 EPS, 0.00% or $0.00 from last year’s $3.35 per share. AGN’s profit will be $1.11 billion for 10.86 P/E if the $3.35 EPS becomes a reality. After $4.86 actual EPS reported by Allergan plc for the previous quarter, Wall Street now forecasts -31.07% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News